Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, a c-MET inhibitor for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, a inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; and HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma, as well as HMPL-689, a treatment for indolent non-Hodgkin's lymphoma and healthy volunteers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorN/A
CIKN/A
Phone+85221213888
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales£214.11 million
Profitability
Miscellaneous
Employees714
Next Earnings DateN/A
OptionableNot Optionable
Hutchison China MediTech (LON:HCM) Frequently Asked Questions
What is Hutchison China MediTech's stock symbol?
Hutchison China MediTech trades on the London Stock Exchange (LON) under the ticker symbol "HCM."
What price target have analysts set for HCM?
1 analysts have issued 12-month price objectives for Hutchison China MediTech's shares. Their predictions range from GBX 5,940 to GBX 5,940. On average, they expect Hutchison China MediTech's share price to reach GBX 5,940 in the next year. This suggests a possible upside of 30.5% from the stock's current price. View Analyst Price Targets for Hutchison China MediTech.
What is the consensus analysts' recommendation for Hutchison China MediTech?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hutchison China MediTech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hutchison China MediTech.
Has Hutchison China MediTech been receiving favorable news coverage?
Headlines about HCM stock have been trending positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hutchison China MediTech earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future.
Who are some of Hutchison China MediTech's key competitors?
Some companies that are related to Hutchison China MediTech include Dechra Pharmaceuticals (DPH), Mayne Pharma Group (MYX), Vectura Group (VEC), Medical Developments International (MVP), Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Opthea (OPT), Trilogy International Partners (TRL), Pharmaxis (PXS), Allergy Therapeutics (AGY), Vita Life Sciences (VLS), Futura Medical (FUM), Avivagen (VIV), Cathay International (CTI) and Recce Pharmaceuticals (RCE).
What other stocks do shareholders of Hutchison China MediTech own?
Who are Hutchison China MediTech's key executives?
Hutchison China MediTech's management team includes the folowing people:
- Mr. Chi Keung To B.Sc., M.B.A., BSc, ACGI, MBA, Exec. Chairman (Age 67)
- Mr. Christian Hogg B.Sc., M.B.A., BSc, MBA, CEO & Exec. Director (Age 53)
- Mr. Johnny Cheng C.A., BEc, CA, CFO & Exec. Director (Age 52)
- Dr. Weiguo Su B.Sc., Ph.D., Chief Scientific Officer, Exec. VP & Exec. Director (Age 62)
- Ms. Edith Shih B.S., M.A., BSE, MA, EdM, Solicitor, FCIS, FCS(PE), Company Sec. & Non-Exec. Director (Age 67)
How do I buy shares of Hutchison China MediTech?
Shares of HCM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Hutchison China MediTech's stock price today?
One share of HCM stock can currently be purchased for approximately GBX 4,550.
How big of a company is Hutchison China MediTech?
Hutchison China MediTech has a market capitalization of £3.03 billion and generates £214.11 million in revenue each year. Hutchison China MediTech employs 714 workers across the globe.
What is Hutchison China MediTech's official website?
How can I contact Hutchison China MediTech?
The company can be reached via phone at +85221213888.
MarketBeat Community Rating for Hutchison China MediTech (LON HCM)
MarketBeat's community ratings are surveys of what our community members think about Hutchison China MediTech and other stocks. Vote "Outperform" if you believe HCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
